03/20/2026
FB102-301 is a phase 2 clinical trial assessing FB102, a potential celiac disease treatment that may prevent inflammation and damage in the small intestine in people with celiac disease.
You may be eligible to participate if you:
โ Are 18-70 years old
โ Have celiac disease confirmed by biopsy and blood serology more than 12 months ago
โ Have maintained a gluten-free diet for at least 12 months
Additional eligibility requirements apply ๐
Up to 100 participants are being enrolled at 30 sites across the US. To learn more about FB102-301 and find a site near you, visit the study website.